Kyntra Bio KYNB
NASDAQ KYNB
$3.20 -0.29 (-8.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Kyntra Bio (KYNB) Liabilities from Discontinued Operations (2023 - 2025)

Updated

Kyntra Bio (KYNB) recorded Liabilities from Discontinued Operations of $156,000 in Q2 2025, down 17.5% from the prior quarter.

Analysis

Kyntra Bio (KYNB) Liabilities from Discontinued Operations (2023 - 2025) Analysis & Trends

At the end of FY2024, Kyntra Bio reported Liabilities from Discontinued Operations of $356,000, down 76.3% from FY2023.

  • Across earlier years, Liabilities from Discontinued Operations came in at $1.5 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Kyntra Bio 12.57 Mn -395.37 Mn 1.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 156,000.00
Mar 31, 2025 189,000.00
Dec 31, 2024 356,000.00
Dec 31, 2023 1.50 Mn
API Access

Kyntra Bio Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=KYNB&period=max&api_key=YOUR_API_KEY